The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
MS Treatments
Jahr
Publikationsjahr
2025
Autoren
Autorenliste der Publikation
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Ziemssen T, Reich DS; HERCULES Trial Group.
Verlag
Publisher-Information
N Engl J Med. 2025 May 15;392(19):1883-1892.
Link
Zur Publikation (externer Server)
https://doi.org/10.1056/nejmoa2415988
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2025
Serum glial fibrillary protein reflects early brain injury dynamics and cognitive changes after deep brain stimulation surgery
NIL
Jahr
2025
A roadmap for safe, regulation-compliant Living Labs for AI and digital health development
MASC
Jahr
2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study
NIL
Jahr
2025
Variations in neuronal cytoskeletal integrity affect directed communication in distributed networks during inhibitory control
Multiple Sclerosis
Jahr
2025
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
NIL
Jahr
2025